OTHER INFORMATION
−Removed: the fiscal quarter ended September 30, 2023, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Securities
+Added: the fiscal quarter ended December 31, 2023, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Securities
Exchange Act of 1934, as amended) adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as
such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933, as amended).
−Removed: Employment Agreement, dated September 5, 2023, between Elite Pharmaceuticals, Inc.
−Removed: and Carter Ward (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on September 7, 2023).
Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a) and Rule 15d-14(a)*
4 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
−Removed: Instance Document
−Removed: Taxonomy Schema Document
−Removed: Taxonomy Extension Calculation Linkbase Document
−Removed: Taxonomy Extension Definition Linkbase Document
+Added: XBRL Instance Document
+Added: XBRL Taxonomy Schema Document
+Added: XBRL Taxonomy Extension Calculation Linkbase Document
+Added: XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
−Removed: Taxonomy Extension Presentation Linkbase Document
+Added: XBRL Taxonomy Extension Presentation Linkbase Document
Page Interactive Data File (embedded within the Inline XBRL document)
9 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.